Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: A case-control study

Respirology

Volumn 20, Issue 3, 2015, Pages 445-452

  Sakamoto, Susumu ^a   Muramatsu, Yoko ^a   Satoh, Keita ^a   Ishida, Fumiaki ^a   Kikuchi, Naoshi ^a   Sano, Go ^a   Sugino, Keishi ^a   Isobe, Kazutoshi ^a   Takai, Yujiro ^a   Homma, Sakae ^a  

^a TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

Author keywords

advanced idiopathic pulmonary fibrosis; combination therapy; N acetylcysteine; pirfenidone

Indexed keywords

ACETYLCYSTEINE; PIRFENIDONE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE; SCAVENGER;

ADULT; AGED; ANOREXIA; ARTICLE; BACTERIAL PNEUMONIA; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION TEST; MALE; NAUSEA; PHOTOSENSITIVITY; PRIORITY JOURNAL; SORE THROAT; TREATMENT DURATION; COMBINATION DRUG THERAPY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; IDIOPATHIC PULMONARY FIBROSIS; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY; VITAL CAPACITY;

ACETYLCYSTEINE; ADMINISTRATION, INHALATION; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; PYRIDONES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84924600238     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12477     Document Type: Article

References (30)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183: 788-824.
2. Iyer SN, Gurujeyalakshmi G, Giri SN,. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther. 1999; 291: 367-373.
3. Misra HP, Rabideau C,. Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol. Cell. Biochem. 2000; 204: 119-126.
4. Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A,. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur. J. Pharmacol. 2008; 590: 400-408.
5. Mitani Y, Sato K, Muramoto Y, Karakawa T, Kitamado M, Iwanaga T, Nabeshima T, Maruyama K, Nakagawa K, Ishida K, et al. Superoxide scavenging activity of pirfenidone-iron complex. Biochem. Biophys. Res. Commun. 2008; 372: 19-23.
6. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2005; 171: 1040-1047.
7. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur. Respir. J. 2010; 35 (Suppl. 12-144): 821-829.
8. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-1769.
9. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2083-2092.
10. Homma S, Sugino K, Sakamoto S,. The usefulness of a disease severity staging classification system for IPF in Japan: 20 years of experience from empirical evidence to randomized control trial enrollment. Respir. Investig. 2015; 53: 7-12. doi: http://dx.doi.org/10.1016/j.resinv.2014.08.003.
11. Hunninghake GW,. Antioxidant therapy for idiopathic pulmonary fibrosis. N. Engl. J. Med. 2005; 353: 2285-2287.
12. Cantin AM, Hubbard RC, Crystal RG,. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am. Rev. Respir. Dis. 1989; 139: 370-372.
13. Borok Z, Buhl R, Grimes GJ, Bokser AD, Hubbard RC, Holroyd KJ,. Effect of glutathione aerosol on oxidant-antioxidant imbalance in idiopathic pulmonary fibrosis. Lancet 1991; 338: 215-216.
14. Behr J, Maier K, Degenkolb B, Krombach F, Vogelmeier C,. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am. J. Respir. Crit. Care Med. 1997; 156: 1897-1901.
15. Hagiwara S, Ishii Y, Kitamura S,. Aerosolized administration of N-acetylcysteine attenuates lung fibrosis induced by bleomycin in mice. Am. J. Respir. Crit. Care Med. 2000; 62: 225-231.
16. Muramatsu Y, Sugino K, Sato K, Sakamoto S, Takai Y, Tatebe J, Morita T, Homma S,. Efficacy of inhaled N-acetylcysteine on lung function and redox balance in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011; 183: A1529.
17. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2005; 353: 2229-2242.
18. The Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N. Engl. J. Med. 2012; 366: 1968-1977.
19. The Idiopathic Pulmonary Fibrosis Clinical Research Network. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2093-2101.
20. Bridgeman MM, Marsden M, Selby C, Morrison D, MacNee W,. Effect of N-acetylcysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue. Thorax 1994; 49: 670-675.
21. Cotgreave IA, Eklund A, Larsson K, Moldéus PW,. No penetration of orally administered N-acetylcysteine into bronchoalveolar lavage fluid. Eur. J. Respir. Dis. 1987; 70: 73-77.
22. Homma S, Azuma A, Taniguchi H, Ogura T, Mochiduki Y, Sugiyama Y, Nakata K, Yoshimura K, Takeuchi M, Kudoh S, et al. Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis. Respirology 2012; 17: 467-477.
23. King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, et al. INSPIRE Study Group. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009; 374: 222-228.
24. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE Jr, Idiopathic Pulmonary Fibrosis Study Group. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2004; 350: 125-133.
25. King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, Stähler G, Leconte I, Roux S, Raghu G,. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2008; 177: 75-81.
26. Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR,. Imatinib-IPF study investigators. Imatinib treatment for IPF: randomized placebo controlled trial results. Am. J. Respir. Crit. Care Med. 2010; 181: 604-610.
27. Baldwin ED, Cournand A, Richards DW,. Pulmonary insufficiency; physiological classification, clinical methods of analysis, standard values in normal subjects. Medicine (Baltimore) 1948; 27: 243-278.
28. Burrows B, Kasik JE, Niden AH, Barclay WR,. Clinical usefulness of the single-breath pulmonucy diffusing capacity test. Am. Rev. Respir. Dis. 1961; 84: 789-806.
29. Richeldi L, Ryerson CJ, Lee JS, Wolters PJ, Koth LL, Ley B, Elicker BM, Jones KD, King TE Jr, Ryu JH, et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax 2012; 67: 407-411.
30. Sakamoto S, Itoh T, Muramatsu Y, Satoh K, Ishida F, Sugino K, Isobe K, Homma S,. Efficacy of pirfenidone in patients with advanced-stage idiopathic pulmonary fibrosis. Intern. Med. 2013; 52: 2495-2501.